Tag: Pharnext
PHARNEXT: Pharnext raises 1 MEUR per OCEANE-BSA issue – 01/25/2023 at 6:30 pm
PARIS, France, January 25, 2023 at 6:30 p.m. (CET) – Pharnext SA (FR001400BV89 – ALPHA) (the “Company”), a late-stage biopharmaceutical company developing new therapies for neurodegenerative diseases without satisfactory therapeutic…
Pharnext: AG in sight, transformation project into SCA – 01/24/2023 at 12:12
(CercleFinance.com) – Pharnext announced Tuesday its intention to convene its shareholders next month in order to provide itself with the legal and financial framework adapted to its partnership with Neovacs.…
Pharnext: an agreement governs financing by Neovacs – 01/19/2023 at 12:22
(CercleFinance.com) – Pharnext and Neovacs announced on Thursday the signing of an agreement intended to govern their financing and strategic support agreement presented at the end of 2022. This agreement…
Pharnext: further strengthened links with Neovacs – 2022-12-29 at 12:01
(CercleFinance.com) – Pharnext shares soared on the Paris Stock Exchange on Thursday following the presentation of a series of measures aimed at ensuring the next steps in the development of…
Neovacs: reinforced support measures for Pharnext – 2022-12-29 at 13:00
(CercleFinance.com) – Neovacs, a biotechnology company specializing in therapeutic vaccines, announced Thursday that it would strengthen its ties with Pharnext in order to ensure the next stages of development of…
Pharnext strengthens its ties with Neovacs to ensure the next stages of its development – 2022-12-28 at 20:00
PARIS, France, December 28, 2022 at 8:00 p.m. (CET) – Pharnext SA (FR001400BV89 – ALPHA) (the “Company”), an advanced clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases with no…
NEOVACS: PHARNEXT STRENGTHENS ITS TIES WITH NEOVACS TO ENSURE THE NEXT STEPS OF ITS DEVELOPMENT – 2022-12-28 at 20:00
Paris, December 28, 2022 – 8:00 p.m. CET – Neovacs (Euronext Growth Paris: ALNEV), a French biotechnology company specializing in therapeutic vaccines targeting the treatment of autoimmune diseases and the…
Pharnext strengthens its ties with Neovacs to ensure its development – 2022-12-29 at 08:47
(AOF) – Pharnext SA, a late-stage biopharmaceutical company, today announces a series of decisions aimed at securing the next stages of its development with the support of Neovacs (a French…
The Board of Directors of Pharnext takes note of the resignation of Dr. David Horn SOLOMON from his position as Chief Executive Officer and Director of the Company – 11/28/2022 at 08:30
PARIS, France, November 28, 2022 at 8:30 a.m. (CET) – Pharnext SA (FR001400BV89 – ALPHA) (the “Company”), an advanced clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases with no…
Pharnext: CEO David Solomon resigns with immediate effect
Receive daily value for free every morning The data collected is essential for this processing and is intended for the relevant departments of BFM Bourse and, where applicable, its service…
Pharnext: CEO David Solomon resigns with immediate effect
(CercleFinance.com) – Pharnext announced Monday the resignation with immediate effect of its managing director David Solomon and his replacement on an interim basis by Joshua Schafer, the current chairman of…
Pharnext: the reverse stock split is effective – 11/23/2022 at 11:12 am
(CercleFinance.com) – Pharnext announced on Wednesday that it had consolidated its shares at the rate of one new share against 5,000 old shares, an operation intended to reduce the volatility…